Diagnostic Performance of 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and Prostate-specific Membrane Antigen Results-Reference-Cited by-同舟云学术

Diagnostic Performance of 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and Prostate-specific Membrane Antigen Results

Published:2023-09 Issue:5 Volume:9 Page:832-837
ISSN:2405-4569
Container-title:European Urology Focus
language:en
Short-container-title:European Urology Focus

Author:

Esen Baris,Seymen Hulya,Tarim Kayhan,Koseoglu Ersin,Bolukbasi Yasemin,Falay Okan,Selçukbiricik Fatih,Molinas Mandel Nil,Kordan Yakup,Demirkol Mehmet Onur,Tilki Derya,Esen Tarık

Publisher

Elsevier BV

Subject

Urology

Reference22 articles.

1. Trends in incidence of metastatic prostate cancer in the US;Desai;JAMA Netw Open,2022

2. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer;Mottet,2022

3. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3;Scher;J Clin Oncol,2016

4. Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?;Esen;Eur Urol Focus,2020

5. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study;Hofman;Lancet,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience;ESMO Open;2024-05

2. A multidisciplinary approach to address unmet needs in the management of patients with non-metastatic castration-resistant prostate cancer;Prostate Cancer and Prostatic Diseases;2024-03-02

3. PSMA PET/CT in diagnostiek en responsevaluatie in patiënten met primair gemetastaseerd prostaatkanker;Tijdschrift voor Urologie;2024-02-28